EED-IN-4
EED-IN-4 is an orally active, EZH2-selective immunomodulator and EED-H3K27me3 inhibitor (EED, IC50=28.21 nM) with anti-inflammatory activity. In mouse models, EED-IN-4 preferentially and persistently accumulates in lymph nodes after oral administration. By reducing the H3K27me3 level of dendritic cells and inhibiting their migration, EED-IN-4 reduces the infiltration of immune cells into the central nervous system and effectively alleviates spinal cord inflammation. EED-IN-4 shows weak inhibitory activity against hERG channels and is non-mutagenic, with no obvious toxicity observed upon long-term oral administration. EED-IN-4 can be used for the research of multiple sclerosis.
For research use only. We do not sell to patients.
- Formula: C22H20FN5O
- Molecular Weight:389.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
EED-IN-4 (compound 19) (5 μM; 24 h) reduces the level of H3K27me3 in DC2.4 cells by 79.94% and inhibits cell migration induced by CCL19/CCL21[1].
EED-IN-4 only weakly inhibits hERG channel currents in stably transfected HEK293T cells, with an IC50 >10 μM[1].
EED-IN-4 exhibits high selectivity for EED over the methyltransferase activity of EZH2[1].
EED-IN-4 shows negative results in the Mini-Ames mutagenicity assay containing Salmonella typhimurium TA100[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:DC2.4 dendritic cells
-
Concentration:5 μM
-
Incubation Time:24 h
-
Result:Reduced H3K27me3 protein levels in DC2.4 cells by 79.94% compared to control.
-
Cell Line:DC2.4 dendritic cells
-
Concentration:5 μM
-
Incubation Time:24 h (pre-treatment); 12 h (migration assay)
-
Result:Suppressed CCL19/CCL21-induced migration of DC2.4 cells by 60.64%, which is 1.6-fold greater efficacy than the positive control EED226.
Parmacokinetics
| Species | Dose | Route | Tmax | T1/2 | Cmax | AUC0-t | AUC0-∞ |
|---|---|---|---|---|---|---|---|
| Rat[1] | 10 mg/kg | i.g. | 1.00 h | 2.74 h | 495.43 ng/mL | 3951.73 ng·h/mL | 3964.15 ng·h/mL |
In Vivo
EED-IN-4 (100 mg/kg; p.o.; twice daily; for consecutive 30 days) shows no obvious acute or subacute toxicity in the C57BL/6 mouse model (with equal numbers of male and female mice). The mice exhibit normal body weight gain, no significant abnormalities in blood routine, liver and kidney function indices, and no histopathological damage in major organs including the heart, liver, spleen, lung and kidney[1].
EED-IN-4 (80 mg/kg; intragastric administration (i.g.); single dose) preferentially and persistently accumulates in key immune lymph nodes including axillary, inguinal and cervical lymph nodes in healthy female C57BL/6 mice, with a concentration significantly higher than that of EED226, exhibiting favorable lymphoid tissue tropism[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C57BL/6 mice, 8 weeks old, experimental autoimmune encephalomyelitis (EAE) model[1]
-
Dosage:40 mg/kg, 80 mg/kg
-
Administration:p.o.; twice daily; from day 9 to day 30 post-immunization
-
Result:Dose-dependently reduced disease susceptibility and alleviated clinical symptoms throughout the disease course. It significantly suppressed inflammatory cell infiltration in the spinal cord, decreased the proportions of total CD11c+ DCs, mature DCs (CD11c+CD80+ or CD11c+MHC-II+), F4/80+CD11b+ macrophages, F4/80+CD80+ inflammatory macrophages, and pro-inflammatory Th1 (CD4+IFN-γ+) and Th17 (CD4+IL-17+) T cells in peripheral lymph nodes.
Also reduced the infiltration of CD11c+ DCs, CD11b+ macrophages, and CD4+ T cells into the spinal cord and brain of EAE mice.
Chemical Information
-
Molecular Weight 389.43
-
Formula C22H20FN5O
-
SMILES
CN(C)C1=CC=C(C2=CN=C(NCC3=C(F)C=CC4=C3CCO4)C=C2C#N)C=N1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Cotton Pellet Granuloma
Cotton pellet granuloma is a classical in vivo chronic inflammation model used to evaluate the anti-inflammatory potential of test substances by measuring their ability to inhibit granuloma tissue formation around an implanted foreign body (cotton pellet) in rodents. The method is based on the biological response to a sterile implanted material, which induces proliferative phase inflammation characterized by fibroblast proliferation and collagen-rich granuloma formation, and the final readout reflects the extent of chronic inflammatory tissue growth surrounding the pellet. In multiple preclinical pharmacological evaluations, inhibition of cotton pellet-induced granuloma formation has been used as an indicator of anti-inflammatory activity in both synthetic and natural product screening contexts.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Carrageenan-Induced Paw Edema
Carrageenan-induced paw edema is an acute inflammation model in which intraplantar injection of carrageenan induces localized inflammatory swelling characterized by vascular permeability, leukocyte infiltration, and production of inflammatory mediators such as prostaglandins and cytokines, making it widely used to evaluate anti-inflammatory agents in vivo. The resulting paw volume or thickness increase is quantified over time as a direct readout of inflammatory intensity and drug efficacy, typically reflecting cyclooxygenase-mediated prostaglandin-driven edema formation and immune cell recruitment in peripheral tissue[20].
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Monocyte-derived dendritic cell differentiation
Human monocyte-derived dendritic cells are generated by isolating PBMC-derived monocytes and culturing them with GM-CSF plus IL-4, which produces cells with dendritic-cell antigen-presenting properties, reduced monocyte phenotype, and increased dendritic-cell functional readouts such as antigen uptake, allogeneic T-cell stimulation, and expression of markers including HLA-DR, CD80, CD86, CD83, CD1a, or CD209 depending on protocol and maturation state. The main readout is phenotypic and functional differentiation: immature MoDCs are commonly evaluated by loss or reduction of CD14 with acquisition of dendritic-cell markers and antigen uptake capacity, whereas mature MoDCs are evaluated by increased CD83, CD80, CD86, HLA-DR, and T-cell stimulatory function after exposure to maturation stimuli such as TNF-α or a cytokine/PGE2 cocktail.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)